公开(公告)号：US20240156938A1

公开(公告)日：2024-05-16

申请号：US18506636

申请日：2023-11-10

Applicant: Board of Regents, The University of Texas System

Inventor： GUANGMING ZHONG

IPC: A61K39/118 ,  A61K9/00 ,  A61P31/04 ,  C07K14/005 ,  C12N1/20

CPC classification number: A61K39/118 ,  A61K9/0053 ,  A61P31/04 ,  C07K14/005 ,  C12N1/205 ,  A61K2039/523

Abstract: Disclosed herein, are compositions and methods using Chlamydia muridarum organisms in the treatment and prevention of human Chlamydia trachomatis infections in a subject. Also, disclosed herein are compositions and methods for eliciting an immune response in a subject and for use as vectors.

公开(公告)号：US20240139336A1

公开(公告)日：2024-05-02

申请号：US18296642

申请日：2023-04-06

Applicant: The Regents of the University of Michigan

Inventor： Yu Lei ,  Yee Sun Tan ,  Kanokwan Sansanaphongpricha ,  Duxin Sun ,  Hongwei Chen ,  Hongxiang Hu

IPC: A61K47/69 ,  A61K39/00 ,  A61K39/02 ,  A61K39/118 ,  A61K39/385 ,  A61K47/64 ,  A61P35/00

CPC classification number: A61K47/6929 ,  A61K39/0003 ,  A61K39/0011 ,  A61K39/02 ,  A61K39/118 ,  A61K39/385 ,  A61K47/643 ,  A61K47/646 ,  A61K47/6923 ,  A61P35/00 ,  A61K2039/55561 ,  A61K2039/572 ,  A61K2039/60 ,  A61K2039/622 ,  B82Y5/00

Abstract: The present invention provides methods, compositions, systems, and kits comprising nano-satellite complexes and/or serum albumin carrier complexes, which are used for modulating antigen-specific immune response (e.g., enhancing anti-tumor immunity). In certain embodiments, the nano-satellite complexes comprise: a) a core nanoparticle complex comprising a biocompatible coating surrounding a nanoparticle core; b) at least one satellite particle attached to, or absorbed to, the biocompatible coating; and c) an antigenic component conjugated to, or absorbed to, the at least one satellite particle component. In certain embodiments, the complexes further comprise: d) a type I interferon agonist agent. In some embodiments, the serum albumin complexes comprise: a) at least part of a serum albumin protein, b) an antigenic component conjugated to the carrier protein, and c) a type I interferon agonist agent.

公开(公告)号：US20230112697A1

公开(公告)日：2023-04-13

申请号：US17931356

申请日：2022-09-12

Applicant: UNIVERSITY OF KANSAS

Inventor： Wendy L. PICKING ,  William D. PICKING

IPC: A61K39/118 ,  A61K39/02 ,  A61K39/104

Abstract: Disclosed are compositions comprising a Gram negative needle tip protein and a translocator protein and methods of their use.

公开(公告)号：US11541108B2

公开(公告)日：2023-01-03

申请号：US16609097

申请日：2018-04-30

Applicant: Kansas State University Research Foundation

Inventor： Roman R. Ganta ,  Ying Wang

IPC: A01N63/00 ,  A61K39/02 ,  A61K39/118 ,  C12N1/20 ,  A61K39/00

Abstract: Targeted disruption of a specific gene and its subsequent restoration in obligate intracellular bacteria remains extremely challenging due to their absolute requirement for residence inside a host cell to replicate. Here, targeted allelic exchange mutations were created to inactivate two genes and then to restore one of the two genes of a rickettsial pathogen, Ehrlichia chaffeensis. These methods were then also successfully utilized in Ehrlichia canis and Anaplasma phagocyophilum. The resultant mutated pathogens are useful in immunogenic compositions for reducing the incidence of or severity of infection with ricksettsial pathogens.

公开(公告)号：US11485973B2

公开(公告)日：2022-11-01

申请号：US17029860

申请日：2020-09-23

Applicant: SNIPR Biome ApS

Inventor： Morten Sommer ,  Virginia Martinez ,  Eric Van der Helm ,  Jakob Krause Haaber ,  Ana De Santiago Torio ,  Christian Grøndahl ,  Jasper Clube

IPC: A61K39/00 ,  A61K39/38 ,  A61K39/02 ,  A61K39/09 ,  A61K39/085 ,  A61K39/10 ,  A61K39/08 ,  A61K39/102 ,  A61K39/118 ,  C12N15/11 ,  A61P31/04 ,  A61K39/395 ,  A61K38/46 ,  C07K16/28

Abstract: The invention provides methods for treating or preventing microbial (eg, bacterial) infections and means for performing these methods. In particular, treatment of infections requiring rapid and durable therapy is made possible, such as for treating acute conditions such as septicemia, sepsis, SIRS or septic shock. The invention is particularly useful, for example, for treatment of microbes such as for environmental, food and beverage use. The invention relates inter alia to methods of controlling microbiologically influenced corrosion (MIC) or biofouling of a substrate or fluid in an industrial or domestic system. The invention also useful for the treatment of pathogenic bacterial infections in subjects receiving a treatment for a disease or condition, such as a transplant or a treatment for cancer, a viral infection or an autoimmune disease.

公开(公告)号：US20220160861A1

公开(公告)日：2022-05-26

申请号：US17552256

申请日：2021-12-15

Applicant: CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS) ,  UNIVERSITE PARIS DIDEROT PARIS 7 ,  INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM)

Inventor： Philippe VERBEKE ,  Colette KANELLOPOULOS

IPC: A61K39/118 ,  A61P31/04 ,  G01N33/569

Abstract: The invention relates to vaccine compositions for treating and/or preventing infections by a bacterium of the Chlamydiaceae family, said compositions comprising bacteria of the Chlamydiaceae family, which have been previously treated by at least one peptidoglycan inhibitor, or extracts of said treated bacteria.

公开(公告)号：US10794911B2

公开(公告)日：2020-10-06

申请号：US16571032

申请日：2019-09-13

Applicant: Simple HealthKit, Inc.

Inventor： Sheena Ruby Menezes ,  Jerzy Majka ,  Linus Ryan Aranha ,  Quynh Nga Thi Le

IPC: G01N33/53 ,  G01N33/571 ,  C12Q1/00 ,  C12Q1/68 ,  A61K49/00 ,  A61B5/055 ,  A61K39/095 ,  A61K39/118 ,  A61K39/00 ,  G01N33/569

Abstract: A system and method for detecting status of a health condition in a single-step process includes: a signal output device including a) a loading zone; b) a reaction zone fluidly coupled to the loading zone and including one or more reaction substances conjugated to labels, configured to enable detection of target material associated with the health condition; c) a testing zone fluidly coupled to the reaction zone and including one or more testing substances corresponding to the target material; and d) a control zone including a control substance retained at the control zone. The system and methods can be adapted for assessment of sexual health of one or more subjects, in relation to pregnancy, fertility, and/or sexually transmitted infections caused by one or more agents including, Chlamydia trachomatis, Neisseria gonorrhoeae, Trichomonas vaginalis, Treponema pallidum, Gardnerella vaginitis, human immunodeficiency virus, human papillomavirus infection, Hepatitis B, and herpes simplex virus.

公开(公告)号：US20200254088A1

公开(公告)日：2020-08-13

申请号：US16760160

申请日：2018-11-05

Applicant: Intervet Inc.

Inventor： Zhichang Xu ,  Rhonda LaFleur ,  Ian Tarpey

IPC: A61K39/295 ,  A61K39/118

Abstract: The present invention provides new multivalent vaccines for felines. The present invention also provides methods of making and using the multivalent vaccines alone or in combinations with other protective agents.

公开(公告)号：US20200215179A1

公开(公告)日：2020-07-09

申请号：US16679920

申请日：2019-11-11

Applicant: President and Fellows of Harvard College ,  Massachusetts Institute of Technology ,  The Brigham and Women's Hospital, Inc.

Inventor： Georg Stary ,  Aleksandar Filip Radovic-Moreno ,  Pamela A. Basto ,  Michael N. Starnbach ,  Robert S. Langer ,  Omid C. Farokhzad ,  Ulrich Von Andrian

IPC: A61K39/118 ,  A61K39/02 ,  A61K39/04 ,  A61K31/711 ,  A61K39/085 ,  A61K45/06 ,  A61K39/09 ,  A61K31/4745

Abstract: Provided herein are new compositions including an inactivated pathogen and one or more adjuvant-loaded polymeric nanoparticles, wherein the adjuvant-loaded nanoparticles are bound to the inactivated pathogen. These compositions are useful for preventing and/or treating diseases caused by the specific pathogens, especially when administered to a subject's mucosal membranes.

公开(公告)号：US10688171B2

公开(公告)日：2020-06-23

申请号：US15550110

申请日：2016-02-10

Applicant: OHIO STATE INNOVATION FOUNDATION

Inventor： Thomas Cherpes ,  Rodolfo Vicetti Miguel

IPC: A61K39/002 ,  A61K39/118 ,  C12N5/0781 ,  A61K39/00

Abstract: Disclosed herein is a Chlamydia-activated B cell (CAB) platform. Also disclosed is a method of enhancing a population of B cells, comprising exposing said B cells to Chlamydia spp. under conditions suitable to enhance the population of B cells, such that expansion and differentiation of said B cells takes place, and said B cells are exposed or crosslinked to an antigen. Also disclosed are methods of producing said CABs, and treating a subject in need thereof with said CABs.